

CITATION REPORT

List of articles citing

Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update

DOI: 10.1111/j.1872-034x.2012.01113.x
Hepatology Research, 2013, 43, 147-54.

Source: <https://exaly.com/paper-pdf/56533307/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
156	Hepatocellular carcinoma and sorafenib: too many resistance mechanisms?. 2013 , 62, 1674-5		74
155	The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance. <i>PLoS ONE</i> , 2013 , 8, e78675	3.7	82
154	mTOR mediates the cross-talk of macrophage polarization and autophagy in atherosclerosis. 2014 , 177, 144-5		13
153	Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma. 2014 , 60, 1264-77		60
152	Serum response factor induces epithelial to mesenchymal transition with resistance to sorafenib in hepatocellular carcinoma. 2014 , 44, 129-36		20
151	More effective agents still needed for progressive radioiodine-refractory differentiated thyroid cancer. 2014 , 21, L3-4		2
150	Transcriptomic responses provide a new mechanistic basis for the chemopreventive effects of folic acid and tributyrin in rat liver carcinogenesis. 2014 , 135, 7-18		18
149	Alternol inhibits migration and invasion of human hepatocellular carcinoma cells by targeting epithelial-to-mesenchymal transition. 2014 , 35, 1627-35		15
148	Tamibarotene: a new hope for therapeutic efficacy in hepatocellular carcinoma patients. 2014 , 8, 1-3		5
147	Efficacy and safety of sorafenib in very elderly patients aged 80 years and older with advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2014 , 44, 1329-38	5.1	29
146	Liver autophagy: much more than just taking out the trash. 2014 , 11, 187-200		127
145	KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma. 2014 , 74, 487-95		49
144	Epithelial-mesenchymal transition: molecular pathways of hepatitis viruses-induced hepatocellular carcinoma progression. 2014 , 35, 7307-15		12
143	Destruxin B inhibits hepatocellular carcinoma cell growth through modulation of the Wnt/ β -catenin signaling pathway and epithelial-mesenchymal transition. 2014 , 28, 552-61		26
142	CSN5 silencing reverses sorafenib resistance of human hepatocellular carcinoma HepG2 cells. 2015 , 12, 3902-3908		7
141	Comparison of the Anti-tumor Effects of Selective Serotonin Reuptake Inhibitors as Well as Serotonin and Norepinephrine Reuptake Inhibitors in Human Hepatocellular Carcinoma Cells. 2015 , 38, 1410-4		31
140	The Role of Autophagy in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2015 , 16, 26629-43	6.3	70

139	Design, synthesis and biological evaluation of thiourea and nicotinamide-containing sorafenib analogs as antitumor agents. 2015 , 6, 867-870		15
138	Very-long-chain fatty acid sphingomyelin in nuclear lipid microdomains of hepatocytes and hepatoma cells: can the exchange from C24:0 to C16:0 affect signal proteins and vitamin D receptor?. 2015 , 26, 2418-25		26
137	Development of Alkyne-Containing Pyrazolopyrimidines To Overcome Drug Resistance of Bcr-Abl Kinase. 2015 , 58, 9228-37		19
136	RACK1 modulates apoptosis induced by sorafenib in HCC cells by interfering with the IRE1/XBP1 axis. <i>Oncology Reports</i> , 2015 , 33, 3006-14	3.5	18
135	Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis. 2015 , 6, 6536		80
134	17-Demethoxy-reblastatin, an Hsp90 inhibitor, induces mitochondria-mediated apoptosis through downregulation of Mcl-1 in human hepatocellular carcinoma cells. 2015 , 47, 373-81		9
133	Erlotinib for advanced hepatocellular carcinoma. A systematic review of phase II/III clinical trials. 2016 , 37, 1184-1190		11
132	A Targetable Molecular Chaperone Hsp27 Confers Aggressiveness in Hepatocellular Carcinoma. 2016 , 6, 558-70		29
131	Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer. 2016 , 8,		16
130	Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	24
129	Modulation of Autophagy by Sorafenib: Effects on Treatment Response. 2016 , 7, 151		69
128	Sorafenib treatment in children with relapsed and refractory neuroblastoma: an experience of four cases. 2016 , 5, 1947-9		10
127	Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence. <i>Scientific Reports</i> , 2016 , 6, 22976	4.9	20
126	An indolylquinoline derivative activates DNA damage response and apoptosis in human hepatocellular carcinoma cells. 2016 , 49, 2431-2441		6
125	Positive feedback loop between cancer stem cells and angiogenesis in hepatocellular carcinoma. 2016 , 379, 213-9		40
124	Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma. 2016 , 84, 237-243		15
123	Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells. 2016 , 107, 407-16		81
122	Quercetin promotes the apoptosis of fibroblast-like synoviocytes in rheumatoid arthritis by upregulating lncRNA MALAT1. 2016 , 38, 1507-1514		62

121	Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment. 2016 , 16, 94		32
120	(Z)-3,5,4PTrimethoxystilbene Limits Hepatitis C and Cancer Pathophysiology by Blocking Microtubule Dynamics and Cell-Cycle Progression. 2016 , 76, 4887-96		19
119	Decrease in tumor enhancement on contrast-enhanced CT is associated with improved survival in patients with hepatocellular carcinoma treated with Sorafenib. 2016 , 46, 839-44		1
118	PSMD10/gankyrin induces autophagy to promote tumor progression through cytoplasmic interaction with ATG7 and nuclear transactivation of ATG7 expression. 2016 , 12, 1355-71		83
117	Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling. 2017 , 152, 2022-2036		42
116	Sorafenib induces variations of the DNA methylome in HA22T/VGH human hepatocellular carcinoma-derived cells. 2017 , 51, 128-144		14
115	Combination of wogonin and sorafenib effectively kills human hepatocellular carcinoma cells through apoptosis potentiation and autophagy inhibition. 2017 , 13, 5028-5034		27
114	Arsenite-loaded nanoparticles inhibit the invasion and metastasis of a hepatocellular carcinoma: in vitro and in vivo study. 2017 , 28, 445101		14
113	Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma. 2017 , 139, 804-814		10
112	C2-ceramide enhances sorafenib-induced caspase-dependent apoptosis via PI3K/AKT/mTOR and Erk signaling pathways in HCC cells. 2017 , 101, 1535-1546		35
111	APSA Awardee Submission: Tumor/cancer stem cell marker doublecortin-like kinase 1 in liver diseases. 2017 , 242, 242-249		7
110	The potential of cell sheet technique on the development of hepatocellular carcinoma in rat models. <i>PLoS ONE</i> , 2017 , 12, e0184004	3-7	8
109	High mobility group box 1 promotes sorafenib resistance in HepG2 cells and in vivo. 2017 , 17, 857		10
108	Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy. <i>Oncotarget</i> , 2017 , 8, 32450-32460	3-3	26
107	COX-2/PGE2 Axis Regulates HIF2 α Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib Treatment. 2018 , 24, 3204-3216		42
106	IL-17A promotes the invasion-metastasis cascade via the AKT pathway in hepatocellular carcinoma. 2018 , 12, 936-952		13
105	Effects of gold core size on regulating the performance of doxorubicin-conjugated gold nanoparticles. 2018 , 11, 3396-3410		17
104	Synthesis of novel 6-substituted amino-9-(β -D-ribofuranosyl)purine analogs and their bioactivities on human epithelial cancer cells. 2018 , 28, 235-239		9

103	A microRNA-7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma. 2018 , 67, 216-231		77
102	Nrf2-p62 autophagy pathway and its response to oxidative stress in hepatocellular carcinoma. 2018 , 193, 54-71		98
101	miR-29a suppresses the growth and metastasis of hepatocellular carcinoma through IFITM3. <i>Oncology Reports</i> , 2018 , 40, 3261-3272	3.5	14
100	Nicosamide Inhibits Cell Growth and Enhances Drug Sensitivity of Hepatocellular Carcinoma Cells via STAT3 Signaling Pathway. <i>Journal of Cancer</i> , 2018 , 9, 4150-4155	4.5	17
99	Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors. 2018 , 50, 1-9		139
98	Synergistic effect of ursodeoxycholic acid on the antitumor activity of sorafenib in hepatocellular carcinoma cells via modulation of STAT3 and ERK. 2018 , 42, 2551-2559		7
97	Melatonin Inhibits the Progression of Hepatocellular Carcinoma through MicroRNA Let7i-3p Mediated RAF1 Reduction. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	21
96	Metformin reverses stem cell-like HepG2 sphere formation and resistance to sorafenib by attenuating epithelial-mesenchymal transformation. 2018 , 18, 3866-3872		7
95	Luteolin and sorafenib combination kills human hepatocellular carcinoma cells through apoptosis potentiation and JNK activation. 2018 , 16, 648-653		12
94	Sorafenib and indocyanine green co-loaded in photothermally sensitive liposomes for diagnosis and treatment of advanced hepatocellular carcinoma. 2018 , 6, 5823-5834		12
93	Molecular Targets in Hepatocarcinogenesis and Implications for Therapy. <i>Journal of Clinical Medicine</i> , 2018 , 7,	5.1	14
92	Selective targeting of antiapoptotic BCL-2 proteins in cancer. 2019 , 39, 146-175		39
91	The combination of the glycolysis inhibitor 2-DG and sorafenib can be effective against sorafenib-tolerant persister cancer cells. 2019 , 12, 5359-5373		20
90	Cyclin-dependent kinase inhibitor 2B gene is associated with the sensitivity of hepatoma cells to Sorafenib. 2019 , 12, 5025-5036		4
89	miR-1226-3p Promotes Sorafenib Sensitivity of Hepatocellular Carcinoma via Downregulation of DUSP4 Expression. <i>Journal of Cancer</i> , 2019 , 10, 2745-2753	4.5	12
88	miR-219 regulates liver cancer stem cell expansion via E-cadherin pathway. 2019 , 18, 3550-3561		9
87	Sorafenib-associated hand-foot skin reaction: practical advice on diagnosis, mechanism, prevention, and management. 2019 , 12, 1121-1127		15
86	ICMT contributes to hepatocellular carcinoma growth, survival, migration and chemoresistance via multiple oncogenic pathways. 2019 , 518, 584-589		11

85	TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma. 2019 , 13, 928-945		16
84	B-cell lymphoma-2-associated transcription factor 1 is overexpressed and contributes to sorafenib resistance in hepatocellular carcinoma. <i>Hepatology Research</i> , 2019 , 49, 1329-1340	5-1	3
83	The MAP3K7-mTOR Axis Promotes the Proliferation and Malignancy of Hepatocellular Carcinoma Cells. <i>Frontiers in Oncology</i> , 2019 , 9, 474	5-3	9
82	pH-responsive hyaluronic acid nanoparticles coloaded with sorafenib and cisplatin for treatment of hepatocellular carcinoma. 2019 , 34, 219-228		7
81	A selective c-Met and Trks inhibitor Indo5 suppresses hepatocellular carcinoma growth. 2019 , 38, 130		10
80	Molecular functions and clinical impact of thyroid hormone-triggered autophagy in liver-related diseases. 2019 , 26, 24		28
79	Review: the Role and Mechanisms of Macrophage Autophagy in Sepsis. 2019 , 42, 6-19		54
78	Inhibition of mitochondrial respiration overcomes hepatocellular carcinoma chemoresistance. 2019 , 508, 626-632		11
77	Novel spectrophotometric and factor-based multivariate calibration-prediction techniques for determination of two inhibitors of hepatitis C-virus and hepatocellular carcinoma in pure, human urine, and human plasma. 2019 , 213, 288-300		4
76	O-GlcNAcylation of RAF1 increases its stabilization and induces the renal fibrosis. 2020 , 1866, 165556		5
75	Establishment of a hepatocellular carcinoma patient-derived xenograft platform and its application in biomarker identification. 2020 , 146, 1606-1617		17
74	Deciphering Antitumor Mechanism of Pien Tze Huang in Mice of Hepatocellular Carcinoma Based on Proteomics. 2020 , 2020, 4876251		3
73	CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma. 2020 , 20, 1001		1
72	Sorafenib induces pigmentation via the regulation of Ectenin signalling pathway in melanoma cells. 2020 ,		3
71	Epithelial cell -derived microvesicles: A safe delivery platform of CRISPR/Cas9 conferring synergistic anti-tumor effect with sorafenib. 2020 , 392, 112040		10
70	LncRNA HOTAIR Contributes to Sorafenib Resistance through Suppressing miR-217 in Hepatic Carcinoma. 2020 , 2020, 9515071		15
69	New insights on sorafenib resistance in liver cancer with correlation of individualized therapy. 2020 , 1874, 188382		20
68	RAF1 Expression is Correlated with HAF, a Parameter of Liver Computed Tomographic Perfusion, and may Predict the Early Therapeutic Response to Sorafenib in Advanced Hepatocellular Carcinoma Patients. 2020 , 15, 167-174		3

67	Development of Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer: An Update. 2020 , 10,		2
66	EGFRVIII-specific CAR-T cells produced by piggyBac transposon exhibit efficient growth suppression against hepatocellular carcinoma. 2020 , 17, 1406-1414		6
65	Design, synthesis, and biological evaluation of sorafenib derivatives containing indole (ketone) semicarbazide analogs as antitumor agents. <i>Journal of Heterocyclic Chemistry</i> , 2020 , 57, 2548-2560	1.9	4
64	Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells. 2020 , 20, 332		8
63	Methyl Palmitate-A suitable adjuvant for Sorafenib therapy to reduce in vivo toxicity and to enhance anti-cancer effects on hepatocellular carcinoma cells. 2021 , 128, 366-378		3
62	Dynamic Contrast-Enhanced Magnetic Resonance Imaging as Imaging Biomarker for Vascular Normalization Effect of Infigratinib in High-FGFR-Expressing Hepatocellular Carcinoma Xenografts. 2021 , 23, 70-83		0
61	Curcumin and mitochondria. 2021 , 439-454		
60	MicroRNA miR-509-3p inhibit metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma. 2021 , 12, 2263-2273		4
59	IL-6 plays a crucial role in epithelial-mesenchymal transition and pro-metastasis induced by sorafenib in liver cancer. <i>Oncology Reports</i> , 2021 , 45, 1105-1117	3.5	5
58	Genome-scale CRISPRa screening identifies MTX1 as a contributor for sorafenib resistance in hepatocellular carcinoma by augmenting autophagy. 2021 , 17, 3133-3144		2
57	Addition of apatinib to transarterial chemoembolization leads to improved outcome in patients with intermediate and advanced hepatocellular cancer. 2021 , 9, 2		
56	Strategies to better treat glioblastoma: antiangiogenic agents and endothelial cell targeting agents. <i>Future Medicinal Chemistry</i> , 2021 , 13, 393-418	4.1	1
55	The Effects of Autophagy-Related Genes and lncRNAs in Therapy and Prognosis of Colorectal Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 582040	5.3	2
54	Imaging, Pathology, and Immune Correlates in the Woodchuck Hepatic Tumor Model. <i>Journal of Hepatocellular Carcinoma</i> , 2021 , 8, 71-83	5.3	1
53	Autophagy, an accomplice or antagonist of drug resistance in HCC?. <i>Cell Death and Disease</i> , 2021 , 12, 266	9.8	10
52	Development of Pigmentation-Regulating Agents by Drug Repositioning. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	6
51	Treatment of liver cancer cells with ethyl acetate extract of <i>Crithmum maritimum</i> permits reducing sorafenib dose and toxicity maintaining its efficacy. <i>Journal of Pharmacy and Pharmacology</i> , 2021 , 73, 1369-1376	4.8	3
50	Imaging of treatment response during systemic therapy for hepatocellular carcinoma. <i>Abdominal Radiology</i> , 2021 , 46, 3625-3633	3	1

49	Inhibiting USP8 overcomes hepatocellular carcinoma resistance via suppressing receptor tyrosine kinases. <i>Aging</i> , 2021 , 13, 14999-15012	5.6	1
48	Longitudinal Circulating Levels of miR-23b-3p, miR-126-3p and lncRNA GAS5 in HCC Patients Treated with Sorafenib. <i>Biomedicines</i> , 2021 , 9,	4.8	1
47	The APAC Score: A Novel and Highly Performant Serological Tool for Early Diagnosis of Hepatocellular Carcinoma in Patients with Liver Cirrhosis. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	5
46	Targeting Na ⁺ /K ⁺ -ATPase by berbamine and ouabain synergizes with sorafenib to inhibit hepatocellular carcinoma. <i>British Journal of Pharmacology</i> , 2021 , 178, 4389-4407	8.6	2
45	Therapeutic efficacy of a extract in a rat model of hepatocellular carcinoma: Histopathological aspects. <i>Journal of Traditional and Complementary Medicine</i> , 2021 , 11, 400-408	4.6	0
44	Application of self-assembly peptides targeting the mitochondria as a novel treatment for sorafenib-resistant hepatocellular carcinoma cells. <i>Scientific Reports</i> , 2021 , 11, 874	4.9	1
43	Cytokine Receptors and Signaling. 2016 , 93-129		1
42	Small Molecule-Targeted Therapies for GI Cancers: Success and Failures. <i>Diagnostics and Therapeutic Advances in GI Malignancies</i> , 2020 , 43-57	0.2	1
41	miR-552 Regulates Liver Tumor-Initiating Cell Expansion and Sorafenib Resistance. <i>Molecular Therapy - Nucleic Acids</i> , 2020 , 19, 1073-1085	10.7	22
40	Targeted Gene Silencing BRAF Synergized Photothermal Effect Inhibits Hepatoma Cell Growth Using New GAL-GNR-siBRAF Nanosystem. <i>Nanoscale Research Letters</i> , 2020 , 15, 116	5	3
39	BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib. <i>PLoS ONE</i> , 2013 , 8, e83623.	7.7	53
38	Efficient induction of apoptosis by wee1 kinase inhibition in hepatocellular carcinoma cells. <i>PLoS ONE</i> , 2014 , 9, e100495	3.7	21
37	3β-hydroxysterol Δ4-reductase on the surface of hepatitis C virus-related hepatocellular carcinoma cells can be a target for molecular targeting therapy. <i>PLoS ONE</i> , 2015 , 10, e0124197	3.7	7
36	Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines. <i>PLoS ONE</i> , 2017 , 12, e0174153	3.7	30
35	pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma. <i>Oncotarget</i> , 2016 , 7, 2646-59	3.3	35
34	Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment. <i>World Journal of Gastroenterology</i> , 2014 , 20, 486-97	5.6	15
33	Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2019 , 25, 2365-2372	5.6	17
32	Targeting the insulin-like growth factor pathway in hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2014 , 6, 716-37	3.4	47

31	Role of autophagy in differential sensitivity of hepatocarcinoma cells to sorafenib. <i>World Journal of Hepatology</i> , 2014 , 6, 752-8	3.4	27
30	Engineering of HN3 increases the tumor targeting specificity of exosomes and upgrade the anti-tumor effect of sorafenib on HuH-7 cells. <i>PeerJ</i> , 2020 , 8, e9524	3.1	1
29	Anti-Hepatocellular Carcinoma Biomolecules: Molecular Targets Insights. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	15
28	Solubility Determination, SoluteSolvent Interactions, and Model Correlation of Sorafenib in Twelve Pure Organic Solvents between T = 273.15 and 313.15 K. <i>Journal of Chemical & Engineering Data</i> ,	2.8	2
27	RNAi screening with shRNAs against histone methylation-related genes reveals determinants of sorafenib sensitivity in hepatocellular carcinoma cells. <i>International Journal of Clinical and Experimental Pathology</i> , 2014 , 7, 1085-92	1.4	12
26	Quantitative perfusion- and diffusion-weighted magnetic resonance imaging of gastrointestinal cancers treated with multikinase inhibitors: a pilot study. <i>Gastrointestinal Cancer Research: GCR</i> , 2014 , 7, 75-81		6
25	Exploring the Mechanisms of Arsenic Trioxide () in Hepatocellular Carcinoma Based on Network Pharmacology. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021 , 2021, 5773802	2.3	0
24	Design, synthesis and antitumor activity of novel sorafenib derivatives. <i>Journal of Heterocyclic Chemistry</i> ,	1.9	0
23	Correlation between Immunohistochemical Markers in Hepatocellular Carcinoma Cells and High-Throughput Drug Sensitivity Screening.. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2022 , 2022, 5969716	2.8	
22	In Silico Drug Repurposing Approach: Investigation of FadD32 Targeted by FDA-Approved Drugs.. <i>Molecules</i> , 2022 , 27,	4.8	1
21	Immunotherapy for hepatobiliary cancers: Emerging targets and translational advances. <i>Advances in Cancer Research</i> , 2022 ,	5.9	0
20	Highly Potent Immunotoxins Targeting the Membrane-distal N-lobe of GPC3 for Immunotherapy of Hepatocellular Carcinoma.. <i>Journal of Cancer</i> , 2022 , 13, 1370-1384	4.5	1
19	Formulation of polymeric nanoparticles loaded sorafenib; evaluation of cytotoxicity, molecular evaluation, and gene expression studies in lung and breast cancer cell lines. <i>Nanotechnology Reviews</i> , 2022 , 11, 987-1004	6.3	1
18	Impact of Exogenous Treatment with Histidine on Hepatocellular Carcinoma Cells.. <i>Cancers</i> , 2022 , 14,	6.6	0
17	Broad Transcriptomic Impact of Sorafenib and Its Relation to the Antitumoral Properties in Liver Cancer Cells.. <i>Cancers</i> , 2022 , 14,	6.6	
16	Features of modified response evaluation criteria use in solid tumors in patients with hepatocellular carcinoma. <i>Annals of HPB Surgery</i> , 2022 , 27, 33-39	0.4	
15	High PPT1 expression predicts poor clinical outcome and PPT1 inhibitor DC661 enhances sorafenib sensitivity in hepatocellular carcinoma.. <i>Cancer Cell International</i> , 2022 , 22, 115	6.4	0
14	Heterocyclic compounds: Importance in anticancer drug discovery.. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022 ,	2.2	3

13	Decoding the mechanism of drugs of heterocyclic nature against hepatocellular carcinoma.. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022 ,	2.2	0
12	Data_Sheet_1.PDF. 2019 ,		
11	Novel Thienyl-Based Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma. <i>Journal of Personalized Medicine</i> , 2022 , 12, 738	3.6	0
10	miRNAs and the Hippo pathway in cancer: Exploring the therapeutic potential (Review). <i>Oncology Reports</i> , 2022 , 48,	3.5	0
9	Ursolic acid enhances the antitumor effects of sorafenib associated with Mcl-1-related apoptosis and SLC7A11-dependent ferroptosis in human cancer. <i>Pharmacological Research</i> , 2022 , 182, 106306	10.2	0
8	Inhibition of LPAR6 overcomes sorafenib resistance by switching glycolysis into oxidative phosphorylation in hepatocellular carcinoma. 2022 ,		1
7	Therapeutic Effects of Crocin Alone or in Combination with Sorafenib against Hepatocellular Carcinoma: In Vivo & In Vitro Insights. 2022 , 11, 1645		1
6	The natural medicinal fungus Huaier promotes the anti-hepatoma efficacy of sorafenib through the mammalian target of rapamycin-mediated autophagic cell death. 2022 , 39,		0
5	Mylabris phalerata induces the apoptosis and cell cycle delay in HCC, and potentiates the effect of sorafenib based on the molecular and network pharmacology approach.		0
4	HDLBP Promotes Hepatocellular Carcinoma Proliferation and Sorafenib Resistance by Suppressing Trim71-dependent RAF1 Degradation. 2022 ,		0
3	Target enzymes in serine-glycine-one-carbon metabolic pathway for cancer therapy.		0
2	Autophagy: A challengeable paradox in cancer treatment.		0
1	H2Valdien derivatives induce apoptosis and cell cycle arrest in HepG2 hepatocellular carcinoma cells via a p53-dependent pathway..		0